Recent price performance and context

Mirum Pharmaceuticals (MIRM) stock has been under pressure recently, with the price down about 13% over the past month and 6% over the past week, despite a gain of roughly 5% over the past 3 months.

For longer term holders, the picture looks different. Total returns are about 18% year to date and roughly 106% over the past year, while the 3 year and 5 year total returns are very large multiples of the starting level.

Short term momentum has cooled, with the 30 day share price return down 13.19% and the 7 day share price return down 5.65%. However, the 1 year total shareholder return of 105.86% still reflects a very strong longer term move from earlier levels.

If you are interested in other potential growth stories in healthcare, it could be a good time to scan the rare disease and biotech space via 40 healthcare AI stocks

With Mirum trading below some valuation estimates yet already showing very strong multi year returns, the key question now is whether the recent pullback leaves mispricing on the table or if the market is already discounting future growth.

Most Popular Narrative: 36.3% Undervalued

Mirum's most followed valuation narrative pegs fair value at about $144 per share versus the recent close around $91.84. This sets up a sizeable perceived gap that hinges on rare disease execution and late stage trial outcomes.

Multiple late-stage pipeline catalysts, including three pivotal study readouts (VISTAS, VANTAGE, EXPAND) over the next 24 months and the initiation of the Phase II Fragile X study, set the stage for further product label expansions and new indication launches, underpinning future revenue diversification and potential earnings acceleration.

Want to see what kind of revenue ramp, margin shift, and future earnings multiple are baked into that valuation bridge from today to the narrative fair value? The key moving parts are the projected step up in dollar revenue, a swing from sizeable losses to positive earnings, and a future earnings profile that supports a premium P/E against broader US Biotechs.

Result: Fair Value of $144.15 (UNDERVALUED)

However, this hinges on key risks, including heavy reliance on LIVMARLI and the possibility that competing therapies or tougher reimbursement decisions could undercut the current growth narrative.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another Take on Valuation

On the simple revenue multiple view, Mirum trades on a P/S of 9.8x, which is slightly above its estimated fair ratio of 9.4x but below the US Biotechs peer average of 12.1x. That mix of modest premium to the fair ratio yet discount to peers raises a clear question: is the stock priced for too much, or not quite enough?

Next Steps

With mixed signals across valuation, momentum, and sentiment, the next move is yours. Review the data, pressure test the thesis, and weigh up the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If you stop with just one stock, you could miss other opportunities that better suit your goals, risk comfort, and income needs, so keep widening the net.

• Target potential mispricing by scanning companies that look cheaper than their fundamentals suggest via the 45 high quality undervalued stocks.
• Build a steadier core by focusing on businesses with strong balance sheets and solid financial footing using the solid balance sheet and fundamentals stocks screener (46 results).
• Get ahead of the crowd by tracking a screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.